Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

Prevalence of Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) Following Squamous Cell Carcinomas of the Oropharynx Treatment by Combined Chemoradiotherapy

The study's aim is to determinate the prevalence of obstructive sleep apnea hypopnea syndrome after treatment by combined chemoradiotherapy in a locally advanced stages treated population of oropharyngeal cancer. Indeed, the level of knowledge about the consequences of oropharyngeal cancer treatment on sleep quality remains poor but the few studies published on the subject suggest an increased risk of development of OSAHS for these patients.

Inclusion Criteria:

• Age> 18 years old
• Performance Status 0-2
• Squamous cell carcinoma of the oropharynx treated with concomitant chemoradiotherapy
• Treatment termination time greater than 6 months at inclusion
• Tumor classification (American Joint Committee on Cancer 8th) T2-T4 N0-N3
• Patient in complete remission at inclusion
• patient's consent's obtained after information

Exclusion Criteria:

• Previous treatment for upper aerodigestive tract cancer
• Incomplete radiotherapyTreatment
• Neurological pathology wich may affect the functions of the upper aerodigestive tract
• Pregnant or breastfeeding woman
• Unweaned alcoholism
• Tracheotomized patient at the time of the study
• Patient under protection: subjects with guardianship or under law protection
• No health insurance coverage